Elderly patients with migraine: An open-label study on prophylaxis therapy with levetiracetam

Central Nervous System Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 31-34

  Pizza, V ^a   Busillo, V ^b   Agresta, A ^a   Bisogno, A ^c   Capasso, A ^c  

^a Vallo della Lucania SA   (Italy)

^b Hospital Santa Maria Addolorata   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

Antiepileptics drugs; Levetiracetam; Migraine; Prophylaxis therapy

Indexed keywords

ETIRACETAM; ANTICONVULSIVE AGENT; PIRACETAM;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; MIGRAINE; MORBIDITY; OPEN STUDY; PROPHYLAXIS; SOMNOLENCE; STOMACH PAIN; ANALOGS AND DERIVATIVES; MIDDLE AGED; MIGRAINE DISORDERS; TREATMENT OUTCOME;

AGED; ANTICONVULSANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PIRACETAM; TREATMENT OUTCOME;

EID: 79953022729     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152411794961086     Document Type: Article

References (26)

1. Società Italiana per lo Studio delle Cefalee. Linee Guida Diagnostiche e Terapeutiche dell'emicrania e della cefalea a grappolo. In: Gallai V, Pini LA, Eds. Trattato delle Cefalee. Centro Scientifico Editore: Torino, 2002, L3-L141.
2. Mazzotta G. Ipereccitabilità neuromuscolare latente e test d'ischemia nei pazienti cefalalgici. In: Gallai V, Pini LA eds. Trattato delle Cefalee. Centro Scientifico Editore: Torino, 2002, pp.143-151.
3. Ottman, R.; Lipton, R.B. Comorbidity of migraine and epilepsy. Neurology, 1994, 44, 2105-2110.
4. Cutrer, F.M. Antiepileptic drugs: how they work in headache. Headache, 2001, 41 (Suppl), S3-S10.
5. Ghose, K.; Niven, B. Prophylactic sodium valproate therapy in patients with drug-resistant migraine. Methods Find. Exp. Clin. Pharmacol., 1998, 20, 353-359.
6. McNamara, J.O., Drugs effective in the therapy of the epilepsies. In: Hardman, J.G., Limbird, L.E., Gilman, A., Eds. The pharmacological basis of therapeutics. McGraw Hill, 2004, p. 536.
7. Storey, J.R. Calder, C.S. Hart, D.E. Potter, D.L. Topiramate in migraine prevention: a double-blind placebo-controlled study. Hedache, 2001, 41, 968-975.
8. Sander, J.W.; Mitchell, T.N. Levetiracetam: a new antiepiletic drug for the adjunctive therapy of chronic epilepsy. Drugs Today, 2001, 37, 665-673.
9. Noyer, M.; Gillard, M.; Magagne, A.; Henichart, J.P.; Wulfert, E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act vi a specific binding site in CNS membranes. Eur. J. Pharmacol., 1995, 286, 137-146.
10. Lukyanetz, E.A.; Shkryl, V.M.; Kostyuk, P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia, 2002, 43, 9-18.
11. Patsalos, P.N. The pharmacokinetic characteristics of levetiracetam. Methods Find. Exp. Clin. Pharmacol., 2003, 25, 123-129.
12. Haria M, Balfour JA. Levetiracetam. CNS Drugs, 1997, 7, 159-164.
13. Landmark, C.J. Antiepileptic drugs in non-epilepsy disorders relations between mechanisms of action and clinical efficacy. CNS Drugs, 2008, 22, 27.
14. Pascual-Gómez, J. Papel de los neuromoduladores en el tratamiento preventivo de la migraña. Rev. Neurol., 2009, 49, 25-32-47.
15. Kaniecki, R. Neuromodulators for migraine prevention. Headache, 2008, 48, 586-600
16. Cuvellier, J.C. Antiepileptic drugs for the prevention of pediatric migraine. Rev. Neurol., 2009, 165, 1002-9.
17. Bakola, E.; Skapinakis, P.; Tzoufi, M.; Damigos, D.; Mavreas, V. Anticonvulsant drugs for pediatric migraine prevention: an evidence- based review. Eur. J. Pain, 2009, 13, 893-901.
18. Krusz J.C. Levetiracetam as prophylaxis for resistant headaches. Cephalalgia, 2001, 21, 373.
19. Drake, M.E. Jr, Greathouse, N.I.; Armentbright, A.D. Renner, J.B. Levetiracetam for preventive treatment of migraine. Cephalalgia, 2001, 21, 373.
20. Troost, B.T.; Wiles, R.M. Levetiracetam for treatment of intractable headache. Headache 2003, 43, 588.
21. Gallai, V.; Alberti, A., Rossi, C.; Coppola, F.; Gallai, B.; Mazzotta, G.; Sarchielli, P. An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. J. Headache Pain, 2003, 4, 92-96.
22. Brighino, F. Palermo, A. Aloisio, A. Francolini, M. Giglia, G. Fierro, B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month openlabel study. Clin. Neuropharmacol., 2006, 29, 338-42.
23. Pakalnis, A.; Kring, D.; Meier, L. Levetiracetam prophylaxis in pediatric migraine. An open-label study. Headache, 2007, 47, 427-30.
24. Miller, G.S. Efficacy and safety of levetiracetam in pediatric migraine. Headache, 2004, 44, 238-43.
25. Palmer, J.E.; Chronicle, E.P.; Rolan, P.; Mulleners, W.M. Cortical hyperexcitability is cortical under-inhibition: evidence from a novel functional test of migraine patients. Cephalalgia, 2000, 20, 525-532.
26. Lynch, B.; Lamberg, N.; Nocka, K. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA, 2004, 101, 9861-6.